Comparison of Risperidone and Melatonin Effects in Methylphenidate Treated Children with Attention Deficit Hyperactivity Disorder for Treatment of Sleep Disorders

Gholami Damian F1, Mahmoodi Gharale J1, Sabzali P2, Darabi F3 and Haji Seyed Javadi P4
1Psychiatric, Department of Psychiatry, Ruzbeh Psychiatry Hospital, Tehran University of Medical Sciences, Tehran, Iran
2Psychiatric, Department of Psychiatry Emanhossein Hospital, Shahid beheshti University of Medical Sciences, Tehran, Iran
3Department of Public Health, Asadabad Medical Sciences Faculty, Hamadan University of Medical Sciences, Hamadan, Iran
4Psychiatric, Department of Psychiatry, Tehran University of Medical Sciences, Tehran, Iran
*Corresponding author: Javadi HSP, Psychiatric, Ruzbeh Hospital, Tehran University of Medical Science, Tehran, Iran Tel: 982155413540, Fax: 982155421959, E-mail: p.sedjavadi@gmail.com
Received date: July 13, 2017; Accepted date: July 17, 2017; Published date: July 23, 2017
Copyright: © 2017 Damian GF, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Objectives: Some studies reported a significant improvement in sleep parameters by melatonin therapy in children with ADHD. Utilizing risperidone along with stimulants is another pharmacologic approach for ADHD treatment. In this study we investigated the effect of melatonin and risperidone on sleep disorders in children with ADHD and compared their effectiveness as well.

Methods & Methods: 29 patient aged 6 years to 12 years old with ADHD were randomly divided into two groups based on file number: either received melatonin (3 mg to 6 mg) combined with Ritalin or received risperidone (0.25mg to 0.5 mg) combined with Ritalin in a single blind randomized clinical trial. Assessments were performed at baseline and were repeated at 2 and 4 weeks after beginning of the treatment.

Results: In risperidone group significant differences has been found in total score of sleep disorders (P=0.000), sleep onset and maintenance score (P=0.000), Sleep-wake transition disorders (P=0.000), but no significant differences in breathing (P=0.104), and hyperhidrosis (P=0.105) and excessive daytime sleepiness score (p=0.065), and in arousal group after 2 weeks (p=0.027) and after 4 weeks (p=0.150). comparison of melatonin group in different weeks (Base line with 2 and 4 weeks after treatment), show significant differences in total score of sleep disorders (P=0.000), sleep onset and maintenance score (P=0.000), Sleep-wake transition disorders (P=0.003), excessive daytime sleepiness (P=0.004), but no significant differences in breathing (P=0.068) and arousal (P=0.218) and hyperhidrosis score (P=0.336).

Conclusion: The results showed the equal effect of risperidone and melatonin. It can be concluded that the risperidone has the same effect of melatonin in the treatment of sleep disorders in children with ADHD.

Keywords: Risperidone; Melatonin; Treated; Sleep disorders

Introduction

Obstructive sleep apnea-hypopnea syndrome (OSAHS) is a common condition characterized by repetitive obstruction of the upper airway resulting in daytime sleepiness due to sleep fragmentation caused by an airway obstruction. There are several papers on the prevalence of OSAHS showing that 7% to 26% of men and 2% to 13% of women have an apnea-hypopnea index (AHI) of more than 15 events per hour [1-5]. In Japan, the prevalence of OSAHS in the male working population has increased over the past decade, being estimated at 22.3% in patients with moderate to severe sleep-disordered breathing (SDB) [6]. It is significantly correlated with cardiovascular morbidity and mortality [7,8]. For patients with moderate to severe OSAHS, standard treatment is the continuous positive airway pressure (CPAP) ventilation. Compliance with and tolerance of CPAP are not always favourable, whose adherence rate is low, being 40% to 83% [9,10]. In Japan, CPAP treatment is not covered by health insurance for OSAHS patients with AHI of less than 20 events per hour. Consequently, one of the oral appliances (OA), prosthetic mandibular advancement (PMA), is a solid alternative to manage patients with mild to moderate OSAHS.

PMA causes protrusion of the mandible and tongue and enlarges and stabilizes the upper airway during sleep. Although the PMA has been shown to be effective for patients with mild to moderate OSAHS, adherence is poor [11,12]. Studies on PMA treatment have indicated that about 75% of patients remained adherent after 12 months of treatment, which may decrease to 50% after 5 years. In the PMA treatment, there are several side effects including tooth pain, pain of the temporomandibular joint (TMJ), gum disease, and dry mouth. Therefore, PMA treatments are not indicated for use in all patients who prefer PMA to CPAP, who do not respond to CPAP, or who show failed treatment attempts with CPAP. It is consequently important to develop other treatment options besides PMA for sleep apnea. A newly developed intraoral pressure gradient therapy system (IPGT), the iNAP® Sleep Therapy System (Somnics Inc., Hsinchu, Taiwan), was introduced as an alternative treatment for OSAHS [13]. The feasibility
study explored the abilities and safety of the new device, the iNAP™ Sleep Therapy System, for patients with OSAHS in our clinical sleep laboratory using full-night polysomnography.

Materials and Methods

Subjects

Subjects enrolled in this study were from outpatient clinic at the Child and Adolescent Psychiatric Division of Roozbeh Hospital, which is the university hospital of the Tehran University of medical sciences, located in Tehran, Iran. Inclusion criteria were (1) ages between 6 and 12 years old, inclusive; (2) diagnoses of ADHD according to DSMIV criteria (American Psychiatric Association, 2000); (3) receiving ritalin; (4) suffering from sleep disorders. Exclusion criteria included (1) presence of major depressive disorder, bipolar disorder, psychotic disorder, generalized anxiety disorder or other psychotic disorders; (2)Mental Retardation;(3)Drug intolerance;(4) any contraindications to the use of two drugs; (5) BMI above the 85th percentile. Subjects meeting diagnostic criteria for ODD were not excluded because of the high level of comorbidity of ODD in most ADHD populations, being present in around 30% to 60% of children with ADHD [12]. In this study 16 out of 29 ADHD patients had been diagnosed with ODD.

Study design

This study was a 28-day, randomized, single-blind clinical trial and parallel-arm comparison of melatonin and risperidone. The diagnosis of ADHD with or without comorbidity was achieved through clinical interview and CSI-4 (Child Symptoms Inventory-4) questionnaire which is a DSM-IV-referenced rating scale that screens for emotional and behavioral symptoms of childhood disorders.

To assess clinically significant improvement relative to baseline, we used the Clinical Global improvement (CGI-I) scales rated separately for symptoms of mania, depression, and ADHD. The CGI is rated on a 7-point scale that ranges from 1 (very much improved) to 7 (very much worse). Participants with ADHD had to have Scores 2 (much improved) on the CGI. In addition, socio-demographic information was collected from the parents. This research was approved by the Ethics Committee of Tehran University of Medical Sciences and written informed consent was filled with the participant's parents after full description of the study.

Medication schedule

In this study Subjects were randomly (1:1 ratio) allocated to receive either risperidone or melatonin for 4 weeks. Patients were randomized to a group according to the file number that was odd or even. For children who weighed less than 30 kg, melatonin was given at an initial dose of 3 mg at bedtime and for children upper than 30 kg; 3 mg to 6 mg was given. Besides, risperidone was given 0.25 mg to 0.5 mg for treating sleep problems. Parents were called weekly to monitor progress and discuss possible problems.

Assessment of efficacy and side effects

The parents filled in a 26-item sleep questionnaire(Sleep Disturbance Scale for Children)[13]. Assessments were performed at baseline and were repeated at 2 and 4 weeks after beginning of the treatment. Adverse events were recorded throughout the treatment period. Side effects were then compared between the two trial groups.

Data analysis

The two groups were compared using the X2 or Fisher exact test (categorical variables), Independent Sample t test and Repeated Measure ANOVA (continuous variables) using SPSS 20. Statistical significance was determined at p<0.05.

Results

Pretreatment patients characteristics

Fifty five patients were screened; 30 ADHD patients were eligible to participate in the study. One of the participants due to hypoglycemia excluded from the study. Afterwards from the remaining 29 patients, 15 were assigned to resperidone and 14 were assigned to melatonin. 10 female (4 and 6 were in the resperidone and melatonin group, respectively) and 19 male (11 and 8 were in the resperidone and melatonin group, respectively) were in the study. There were no statistically significant differences between the genders of two groups according to X2 test.

Patients’ quantitative data such as age, body mass index, as well as baseline characteristics were analyzed in two trials before pharmacological intervention. Data analysis showed that there were no significant difference in age (P=0.24), body mass index (P=0.41), total score of sleep disorders (P=0.66), sleep onset and maintenance score (P=0.4), sleep disordered breathing (P=0.67), arousal disorders (P=0.63), sleep-wake transition disorders (P=0.98), excessive daytime sleepiness (P=0.58) and excessive sweating before intervention between two groups (Table 1). There were no significant differences between treatment groups in ODD ratio (P=0.34), and dose of Ritalin effects (P=0.793) in both risperidone and melatonin group.

Comparison of the therapeutic effects (efficacy measure)

The results of SDSC sleep questionnaire were analyzed using ANOVA with repeated measures at baseline, 2 and 4 weeks after the treatment. Data analysis showed that there were no significant difference between two groups in total score of sleep disorders (P=0.339), sleep onset and maintenance score (P=0.212), sleep disordered breathing (P=0.187), arousal disorders (P=0.404), Sleep-wake transition disorders (P=0.858), excessive daytime sleepiness (P=0.349) and excessive sweating (P=0.349).

In a comparison of risperidone group in different weeks(Base line with 2 and 4 weeks after treatment),significant differences has been found in total score of sleep disorders (P=0.000), sleep onset and maintenance score (P=0.000), Sleep-wake transition disorders (P=0.000),but no significant differences in breathing (P=0.104), and hyperhidrosis (P=0.105) and excessive daytime sleepiness score (P=0.065), and in arousal group after 2 weeks (p=0.27) and after 4 weeks (p=0.150).

Comparison of melatonin group in different weeks (Base line with 2 and 4 weeks after treatment), show significant differences in total score of sleep disorders (P=0.000), sleep onset and maintenance score (P=0.000), sleep-wake transition disorders (P=0.003), excessive daytime sleepiness (P=0.004), but no significant differences in breathing (P=0.068) and arousal (P=0.218) and hyperhidrosis score (P=0.336) (Table 2). No statistically significant differences had been observed between the two groups in any of the side effects (Table 3).
Citation: Damian GF, Gharaiie JM, Sabzali P, Darabi F, Javadi HSP (2017) Comparison of Risperidone and Melatonin Effects in Methylphenidate Treated Children with Attention Deficit Hyperactivity Disorder for Treatment of Sleep Disorders. J Sleep Disord Ther 6: 273. doi: 10.4172/2167-0277.1000273

Table 1: Demographic and background data of participant in the study of comparing risperidone and melatonin effect on sleep disorders in children with ADHD.

<table>
<thead>
<tr>
<th>Variables</th>
<th>Risperidone group (N=15)</th>
<th>Melatonin group (N=14)</th>
<th>Statistical analysis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gender</td>
<td>Female 4, Male 11</td>
<td>Female 6, Male 8</td>
<td>χ²(1)=0.840, P=0.359</td>
</tr>
<tr>
<td>Age (Mean ± SD)</td>
<td>8.6 ± 1.8, 9.5 ± 2.21</td>
<td></td>
<td>t(27)=1.2, P=0.24</td>
</tr>
<tr>
<td>Body mass index (Mean ± SD)</td>
<td>27.88 ± 34.33, 49.57±7.1</td>
<td></td>
<td>t(27)=-0.93, P=0.41</td>
</tr>
<tr>
<td>Total score of sleep disorder (Mean ± SD)</td>
<td>51 ± 9.89, 20.15 ± 6.08</td>
<td></td>
<td>t(27)=-0.44, P=0.66</td>
</tr>
<tr>
<td>Sleep onset and maintenance score (Mean ± SD)</td>
<td>17.27 ± 3.71, 18.14 ± 2.8</td>
<td></td>
<td>t(27)=0.71, P=0.48</td>
</tr>
<tr>
<td>Sleep disordered breathing (Mean ± SD)</td>
<td>3.87 ± 1.68, 3.64 ± 1.01</td>
<td></td>
<td>t(27)=-0.43, P=0.67</td>
</tr>
<tr>
<td>Arousals disorders (Mean ± SD)</td>
<td>3.67 ± 1.29, 3.43 ± 1.34</td>
<td></td>
<td>t(27)=-0.49, P=0.63</td>
</tr>
<tr>
<td>Sleep Wake transition disorders (Mean ± SD)</td>
<td>11.4 ± 4.29, 11.36 ± 4.07</td>
<td></td>
<td>t(27)=-0.03, P=0.98</td>
</tr>
<tr>
<td>Excessive daytime sleepiness (Mean ± SD)</td>
<td>11.2 ± 4.04, 10.43 ± 3.39</td>
<td></td>
<td>t(27)=0.71, P=0.48</td>
</tr>
<tr>
<td>Excessive sweating (Mean ± SD)</td>
<td>3.6 ± 2.85, 2.57 ± 1.65</td>
<td></td>
<td>t(27)=-1.18, P=0.25</td>
</tr>
</tbody>
</table>

Table 2: Comparison of melatonin receiving group in the different weeks.

<table>
<thead>
<tr>
<th>Variables</th>
<th>Comparison of baseline with second week</th>
<th>Comparison of baseline with fourth week</th>
<th>Comparison of second week with fourth week</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>t(14) P</td>
<td>t(14) P</td>
<td>t(14) P</td>
</tr>
<tr>
<td>Total Sleep disorder score</td>
<td>5.848 &lt;0.000</td>
<td>9.28 &lt;0.000</td>
<td>2.878 0.013</td>
</tr>
<tr>
<td>Disorders of initiating and maintaining sleep</td>
<td>5.983 &lt;0.000</td>
<td>10.001 &lt;0.000</td>
<td>2.447 0.029</td>
</tr>
<tr>
<td>Sleep Breathing Disorders</td>
<td>1.989 0.068</td>
<td>2.28 0.04</td>
<td>1 0.336</td>
</tr>
<tr>
<td>Disorders of arousal</td>
<td>1.472 0.169</td>
<td>1.295 0.218</td>
<td>1 0.336</td>
</tr>
<tr>
<td>Sleep wake Transition Disorder</td>
<td>3.191 0.007</td>
<td>3.702 0.003</td>
<td>1.343 0.202</td>
</tr>
<tr>
<td>Disorders of excessive somnolence</td>
<td>2.299 0.01</td>
<td>3.44 0.004</td>
<td>1.735 0.106</td>
</tr>
<tr>
<td>Sleep Hyperhidrosis</td>
<td>1 0.336</td>
<td>1 0.336</td>
<td>- -</td>
</tr>
</tbody>
</table>

Table 3: Analysis of side effects in both risperidone and melatonin group.

<table>
<thead>
<tr>
<th>Side effect</th>
<th>Melatonin group</th>
<th>Riper done group</th>
<th>P-value (Fisher exact test)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Headache</td>
<td>0 (0%)</td>
<td>1 (7.14%)</td>
<td>0.483</td>
</tr>
<tr>
<td>Abdominal pain</td>
<td>0 (0%)</td>
<td>2 (14.29%)</td>
<td>0.224</td>
</tr>
<tr>
<td>Morning Somnolence</td>
<td>2 (13.33%)</td>
<td>1 (7.14%)</td>
<td>1</td>
</tr>
<tr>
<td>Increased appetite</td>
<td>2 (13.33%)</td>
<td>0 (0%)</td>
<td>0.483</td>
</tr>
</tbody>
</table>

Discussion

Attention Deficit-Hyperactivity Disorder (ADHD) is the most common psychological disorder in childhood with estimated prevalence of 5.29% worldwide and 10% in Iran [14,15]. The results of this study indicate that there is no significant difference between
risperidone and melatonin in the treatment of sleep disorders in children with ADHD.

The clinician who visit the ADHD children usually focus on improving hyperactivity, attention deficit and impulsiveness. Since the correlation between ADHD and sleep disorder was approved [16,17], it is clear that they should pay enough attention to manage their concomitant sleep disorders.

The effective intervention approaches for ADHD is a combination of different therapeutics strategies including, parent training, cognitive-behavioral and medical therapy by stimulants [18]. Stimulants as the most effective medications for the treatment of ADHD effectively alleviate the symptoms (poor attention, distractibility, hyperactivity and restlessness) [19]. There are a limited number of studies regarding to quality and quantity of sleep in children with ADHD. At present available research results indicate that melatonin can be effective medication in the treatment of insomnia [20].

The results of this study are consistent with the results of previous studies on the effect of melatonin on sleep disorders of ADHD patients. Smits et al. in a double-blind, placebo-controlled study indicated that short-term melatonin administration was relatively safe and significantly more effective than placebo in patients with sleep onset insomnia [21]. Heijden et al. investigated the effect of melatonin treatment on sleep and quality of life. They indicated that melatonin could enhance total asleep time in children with ADHD and chronic sleep onset insomnia [22]. In a double blind randomized clinical trial in Iran with co-administration of melatonin and ritalin significant changes in sleep latency and total sleep disturbance score had been shown in children with ADHD [23].

The effect of risperidone on the quality of sleep has been reported in some studies. For example, Jacobsen [24] reported an improved quality of sleep following treatment with risperidone in affective illness and obsessive-compulsive disorder. In contrast, Daniel et al. [25] reported that patients complained of more insomnia with risperidone and more sedation with clozapine.

It is noteworthy that no statistically significant differences had been observed between the two groups in any of the side effects. Therefore, it can be concluded that the risperidone has the same effect of melatonin in the treatment of sleep disorders in children with ADHD. Since the beneficial effects of melatonin on sleep disorder treatment of patients with ADHD has been proven, the results showed the equal effect of risperidone and melatonin. This prospective follow-up study evaluated a small group of 29 children. A number of issues remain for further investigation. Long-term efficacy and safety of both risperidone and melatonin should be examined in children with ADHD. Additionally, further research is needed with the larger number of subjects and control group to evaluate the clinical impact of risperidone and melatonin.

Limitations

The current research had a number of limitations. It was implemented in 6 years to 12 years. Therefore, these results can be generalized only to adolescent 6 years to 12 years old of Tehran. They could not be generalizable to other geographical areas due to cultural, social, and economic differences.

Acknowledgements

The authors would like to thank all Roozbeh Hospital authorities and administrators for facilitating data collection. They also express their thanks to all participants who participated in this study.

References


